These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 21531577

  • 1. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL, Gomberg-Maitland M, Naeije R, Arneson CP, Lang IM.
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 3. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 4. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP, McDevitt S, Walker S.
    J Heart Lung Transplant; 2012 Aug 04; 31(8):811-6. PubMed ID: 22759797
    [Abstract] [Full Text] [Related]

  • 5. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S, Souza R, Jais X, Fadel E, Ali RH, Humbert M, Dartevelle P, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2007 Apr 04; 26(4):357-62. PubMed ID: 17403477
    [Abstract] [Full Text] [Related]

  • 6. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial.
    Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, Pott GB, Vnencak-Jones CL, Arneson C, Wade M, White RJ, TRUST Study Group.
    J Heart Lung Transplant; 2010 Feb 04; 29(2):137-49. PubMed ID: 20022264
    [Abstract] [Full Text] [Related]

  • 7. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ, Schilz RJ, Barst RJ, Galié N, Rich S, Rubin LJ, Simonneau G, Treprostinil Study Group.
    Chest; 2004 Aug 04; 126(2):420-7. PubMed ID: 15302727
    [Abstract] [Full Text] [Related]

  • 8. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.
    J Heart Lung Transplant; 2011 Dec 04; 30(12):1327-33. PubMed ID: 22055098
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I, Gomez-Sanchez M, Kneussl M, Naeije R, Escribano P, Skoro-Sajer N, Vachiery JL.
    Chest; 2006 Jun 04; 129(6):1636-43. PubMed ID: 16778286
    [Abstract] [Full Text] [Related]

  • 10. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, McLaughlin VV.
    J Heart Lung Transplant; 2013 Sep 04; 32(9):889-96. PubMed ID: 23953817
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
    Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, Glatz J, Jakowitsch J, Lang IM.
    J Heart Lung Transplant; 2012 Jul 04; 31(7):735-43. PubMed ID: 22480725
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
    de Jesus Perez VA, Rosenzweig E, Rubin LJ, Poch D, Bajwa A, Park M, Jain M, Bourge RC, Kudelko K, Spiekerkoetter E, Liu J, Hsi A, Zamanian RT.
    Am J Cardiol; 2012 Nov 15; 110(10):1546-50. PubMed ID: 22853986
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1433-7. PubMed ID: 17010807
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, Torbicki A, Xu KF, Yehle D, Laliberte K, Arneson C, Rubin LJ.
    Circulation; 2013 Feb 05; 127(5):624-33. PubMed ID: 23307827
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ.
    Eur Respir J; 2006 Dec 05; 28(6):1195-203. PubMed ID: 16899485
    [Abstract] [Full Text] [Related]

  • 16. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL, Rayburn BK, Tallaj JA, Pamboukian SV, Bourge RC.
    Chest; 2008 Jul 05; 134(1):139-45. PubMed ID: 18403673
    [Abstract] [Full Text] [Related]

  • 17. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ.
    Am J Respir Crit Care Med; 2005 Dec 15; 172(12):1586-9. PubMed ID: 16151039
    [Abstract] [Full Text] [Related]

  • 18. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
    Sitbon O, Manes A, Jais X, Pallazini M, Humbert M, Presotto L, Paillette Ld, Zaccardelli D, Davis G, Jeffs R, Simonneau G, Galie N.
    J Cardiovasc Pharmacol; 2007 Jan 15; 49(1):1-5. PubMed ID: 17261956
    [Abstract] [Full Text] [Related]

  • 19. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.
    Chest; 2012 Dec 15; 142(6):1383-1390. PubMed ID: 22628490
    [Abstract] [Full Text] [Related]

  • 20. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
    Roman A, Barberà JA, Escribano P, Sala ML, Febrer L, Oyagüez I, Sabater E, Casado MA.
    Appl Health Econ Health Policy; 2012 May 01; 10(3):175-88. PubMed ID: 22452448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.